FilingsTodayDAE HWA Pharm
At a glance
DAE HWA Pharm filed 50 disclosures in the last 12 months, including 14 insider, 4 5% holder, 3 contract and 1 buyback. The most recent key filing was on Oct 16: Chairman sold 3,500 sh on the market at an average ₩13,226, Oct 8–13.
Revenue for 2025 was ₩143B, down 4.2% on 2024. Operating margin was 2.2% against 4.5% a year earlier. Debt was 166% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩78.3B and operating profit of ₩3.8B.
The 2025 annual report lists 369 employees with an average tenure of 6.7 years and average pay of ₩48.4M, #1525 of 1,829 listed companies by average pay. Its 4 directors and auditors were paid ₩155.1M each on average. It paid ₩150 per common share in cash dividends, against ₩150 a year earlier (+0%). 고준진 and related parties held 19.81% at year end.
From the 2025 annual report
Staff: 369 (193 men, 176 women), of whom 32 on fixed-term contracts. Total pay for the year: ₩17.7B. Directors and auditors: 4, paid ₩620.4M in total.
Dividends (common shares)
| Fiscal year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Cash dividend per share | ₩150 | ₩150 | ₩150 |
| Payout ratio | 160.1% | 494.4% | - |
| Yield (as filed) | 0.85% | 1.32% | 1.58% |
| Total cash dividends | ₩2.6B | ₩2.6B | ₩2.6B |
Largest shareholder
고준진 holds 9.17%; with 5 related parties the group holds 19.81% of common shares at year end (from 19.85% at the start of the year).
Auditor: 광교회계법인 · opinion: Unqualified.
Source: 2025 annual business report (DART). How figures are combined
Financial summary
Key filings
Other filings
Links open the original filing on DART, in Korean.